Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bicarbonate dialysate-NYU Langone Health refers to a modified hemodialysis solution and procedure being investigated by NYU Langone Health for patients with end-stage renal disease. The intervention, termed 'isohydric hemodialysis', involves adjusting the sodium bicarbonate concentration in the dialysate fluid—specifically starting at a lower concentration (25 mmol/L) for the first half of the treatment before switching to a standard concentration (37 mmol/L). This approach aims to manipulate the pH-dependent binding of protein-bound uremic retention solutes, such as indoxyl sulfate, to albumin. By altering the pH environment, the treatment seeks to increase the free fraction of these toxins, thereby enhancing their removal during filtration, which is typically inefficient under standard dialysis conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bicarbonate dialysate-NYU Langone Health.